| Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways ER Gimba, TM Tilli Cancer letters 331 (1), 11-17, 2013 | 148 | 2013 |
| Osteopontin-c splicing isoform contributes to ovarian cancer progression TM Tilli, VF Franco, BK Robbs, JLM Wanderley, FR de Azevedo da Silva, ... Molecular Cancer Research 9 (3), 280-293, 2011 | 119 | 2011 |
| A strategy to identify housekeeping genes suitable for analysis in breast cancer diseases TM Tilli, CS Castro, JA Tuszynski, N Carels BMC genomics 17, 1-11, 2016 | 66 | 2016 |
| Toward precision medicine of breast cancer N Carels, LB Spinassé, TM Tilli, JA Tuszynski Theoretical Biology and Medical Modelling 13, 1-46, 2016 | 66 | 2016 |
| Both osteopontin‐c and osteopontin‐b splicing isoforms exert pro‐tumorigenic roles in prostate cancer cells TM Tilli, KD Mello, LB Ferreira, AR Matos, MTS Accioly, PAS Faria, ... The Prostate 72 (15), 1688-1699, 2012 | 64 | 2012 |
| Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia TM Tilli, LC Thuler, AR Matos, CM Coutinho-Camillo, FA Soares, ... Experimental and molecular pathology 92 (1), 13-19, 2012 | 45 | 2012 |
| Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer VH de Almeida, I dos Santos Guimarães, LR Almendra, AMR Rondon, ... Oncotarget 9 (55), 30594, 2018 | 40 | 2018 |
| Ion channel and neurotransmitter modulators as electroceutical approaches to the control of cancer J Tuszynski, TM Tilli, M Levin Current pharmaceutical design 23 (32), 4827-4841, 2017 | 40 | 2017 |
| Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells … TM Tilli, N Carels, JA Tuszynski, M Pasdar Oncotarget 7 (39), 63189, 2016 | 36 | 2016 |
| Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells KDM Nakamura, TM Tilli, JL Wanderley, A Palumbo, RM Mattos, ... Tumor Biology 37, 2655-2663, 2016 | 36 | 2016 |
| A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases N Carels, T Tilli, JA Tuszynski PLoS one 10 (1), e0115054, 2015 | 30 | 2015 |
| Changes in the transcriptional profile in response to overexpression of the osteopontin-c splice isoform in ovarian (OvCar-3) and prostate (PC-3) cancer cell lines TM Tilli, A Bellahcène, V Castronovo, ERP Gimba BMC cancer 14, 1-11, 2014 | 28 | 2014 |
| Antitumor activity of lankacidin group antibiotics is due to microtubule stabilization via a paclitaxel-like mechanism AT Ayoub, RM Abou El-Magd, J Xiao, CW Lewis, TM Tilli, K Arakawa, ... Journal of Medicinal Chemistry 59 (20), 9532-9540, 2016 | 27 | 2016 |
| Biotechnological evolution of siRNA molecules: from bench tool to the refined drug D de Brito e Cunha, ABT Frederico, T Azamor, JG Melgaço, ... Pharmaceuticals 15 (5), 575, 2022 | 18 | 2022 |
| Osteopontin is a tumor autoantigen in prostate cancer patients TM Tilli, EA SILvA, LC Matos, DV Faget, BFP Dias, JSP Vasconcelos, ... Oncology letters 2 (1), 109-114, 2011 | 18 | 2011 |
| Optimization of combination chemotherapy based on the calculation of network entropy for protein-protein interactions in breast cancer cell lines N Carels, TM Tilli, JA Tuszynski EPJ Nonlinear Biomedical Physics 3, 1-18, 2015 | 15 | 2015 |
| Chemical synthesis, pharmacological evaluation and in silico analysis of new 2, 3, 3a, 4, 5, 6-hexahydrocyclopenta [c] pyrazole derivatives as potential anti-mitotic agents M Minu, D Singh, T Mahaddalkar, M Lopus, P Winter, AT Ayoub, ... Bioorganic & Medicinal Chemistry Letters 26 (16), 3855-3861, 2016 | 11 | 2016 |
| Osteopontin-c mediates the upregulation of androgen responsive genes in LNCaP cells through PI3K/Akt and androgen receptor signaling TM Tilli, LB Ferreira Oncology Letters 9 (4), 1845-1850, 2015 | 10 | 2015 |
| Analysis of Inherited Genetic Variants in ret Proto-Oncogene of Brazilian Patients with Apparently Sporadic Medullary Thyroid Carcinoma IM Guerrero, CHC Pessoa, DB Olmedo, ERP Pontes, LC Matos, TM Tilli, ... Thyroid 16 (1), 9-15, 2006 | 8 | 2006 |
| Precision medicine: technological impact into breast cancer diagnosis, treatment and decision making TM Tilli Journal of Personalized Medicine 11 (12), 1348, 2021 | 7 | 2021 |
